Purpose: Ensure appropriate utilization and control of Continuous Glucose Monitors (CGMs)

Why Issue Selected: Continuous Glucose Monitors (CGMs) are devices which can monitor a patient’s glucose levels in the interstitial fluid consistently (every 5 to 15 minutes) versus traditional self-monitoring of blood glucose which is patient initiated at prescribed intervals throughout the day. CGMs allow patients and providers to respond to changing glucose readings more quickly, provide alarms to indicate when glucose levels are outside of threshold levels, and can indicate trends in glucose levels over time. CGMs may also lead to modest improvements in A1C and intensification of glucose control without increasing the risk of hypoglycemia. The 2021 American Association of Clinical Endocrinology Clinical Practice Guideline recommends CGMs for all persons with diabetes treated with intensive insulin therapy, defined as 3 or more injections of insulin per day or the use of an insulin pump, as well as for all individuals with problematic hypoglycemia. MO HealthNet will impose clinical criteria to ensure appropriate utilization of Dexcom G6 products for select participants who desire to utilize CGMs.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Claims</th>
<th>Spend</th>
<th>Avg Spend per Claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEXCOM G6 RECEIVER</td>
<td>1,033</td>
<td>$367,803.42</td>
<td>$333.28</td>
</tr>
<tr>
<td>DEXCOM G6 TRANSMITTER</td>
<td>4,668</td>
<td>$4,279,057.02</td>
<td>$238.53</td>
</tr>
<tr>
<td>DEXCOM G6 SENSOR</td>
<td>12,839</td>
<td>$1,113,502.46</td>
<td>$333.28</td>
</tr>
</tbody>
</table>

Type of Criteria: ☐ Increased risk of ADE ☒ Appropriate Indications ☐ Preferred Drug List ☒ Clinical Edit

Data Sources: ☐ Only Administrative Databases ☒ Databases + Prescriber-Supplied

Drug class for review: Continuous Glucose Monitors (CGMs)
Age range: All appropriate MO HealthNet participants
Documentation of compliance to current therapy OR
- Participant requires insulin administration multiple times per day or use of an insulin pump OR
- Participant has a history of hypoglycemia, a hypoglycemic event, or a comorbidity that poses an unusual challenge with concomitant hypoglycemia or hyperglycemia (e.g., uncontrolled epilepsy) OR
- Participant is visually impaired
- Initial claims must be billed in the following order: 1st receiver, 2nd transmitter, and 3rd sensors

Denial Criteria

- Therapy will be denied if no approval criteria are met
- Claim exceeds quantity limitations:
  - 1 receiver every 310 days
  - 1 transmitter every 76 days
  - 3 sensors every 25 days

Required Documentation

- Laboratory Results:
- Progress Notes:
- MedWatch Form:
- Other:

Disposition of Edit

- Denial: Exception code “0682” (Clinical Edit)
- Rule Type: N

Default Approval Period

- 1 year

References